Bioenergetics of the Staphylococcal Multidrug Export Protein QacA
IDENTIFICATION OF DISTINCT BINDING SITES FOR MONOVALENT AND DIVALENT CATIONS*

Bernadette A. MitchellDagger , Ian T. Paulsen§, Melissa H. Brown, and Ronald A. Skurray

From the School of Biological Sciences, University of Sydney, Sydney, New South Wales 2006, Australia

    ABSTRACT
Top
Abstract
Introduction
References

The multidrug efflux pump QacA from Staphylococcus aureus confers resistance to an extensive range of structurally dissimilar compounds. Fluorimetric analyses demonstrated that QacA confers resistance to the divalent cation 4',6-diamidino-2-phenylindole, utilizing a proton motive force-dependent efflux mechanism previously demonstrated for QacA-mediated resistance to the monovalent cation ethidium. Both the ionophores nigericin and valinomycin inhibited QacA-mediated export of ethidium, indicating an electrogenic drug/nH+ (n >=  2) antiport mechanism. The kinetic parameters, Km and Vmax, were determined for QacA-mediated export of four fluorescent substrates, 4',6-diamidino-2-phenylindole, 3',3'-dipropyloxacarbocyanine, ethidium, and pyronin Y. Competition studies showed that QacA-mediated ethidium export is competitively inhibited by monovalent cations, e.g. benzalkonium, and non-competitively inhibited by divalent cations, e.g. propamidine, which suggests that monovalent and divalent cations bind at distinct sites on the QacA protein. The quaternary ammonium salt, 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene, was used as a membrane-specific fluorescence probe and demonstrated that the amount of substrate entering the inner leaflet was significantly reduced in QacA-containing strains, supporting the notion that the substrate is extruded directly from the membrane.

    INTRODUCTION
Top
Abstract
Introduction
References

The phenomenon of multidrug resistance is widespread in prokaryotic and eukaryotic organisms and is characterized by the ability of a single transmembrane protein to mediate the extrusion of a broad spectrum of structurally disparate toxic substances from the cell. Multidrug resistance pumps operate via an active efflux mechanism and are typically ATP- or PMF1-dependent. Currently, all known ATP-dependent multidrug efflux systems belong to the ABC superfamily of transporters, and the best characterized of these is human P-glycoprotein, which confers resistance to an extensive array of cytotoxic, chemotherapeutic agents used in human cancer cells (1, 2). Another example is LmrA, a P-glycoprotein homolog that has been identified in Lactococcus lactis and represents the first ATP-dependent multidrug efflux system found in bacteria (3). PMF-dependent multidrug efflux proteins have been classified into three distinct families of membrane transport proteins based on comparative sequence analysis: the major facilitator superfamily (4-6), e.g. Bmr from Bacillus subtilis (7) and QacA from Staphylococcus aureus (8, 9); the small multidrug resistance family (10), e.g. EmrE from Escherichia coli (11) and Smr from S. aureus (12, 13); and the resistance/nodulation/cell division family (14), e.g. MexB from Pseudomonas aeruginosa (15) and AcrB from E. coli (16).

The multidrug resistance gene qacA is encoded on multiresistance plasmids from clinical isolates of S. aureus and confers resistance to a wide range of antimicrobial organic cations, including various dyes, Qacs, diamidines, biguanidines, and guanylhydrazones (8, 9, 17). qacA encodes a membrane protein, QacA, with 14 TMS (18) providing resistance to ethidium via a PMF-dependent export mechanism (8). Expression of the qacA gene is negatively regulated by a divergently transcribed regulator, QacR (19). QacA and a closely related protein, QacB, also found in clinical isolates of S. aureus, mediate high levels of resistance to monovalent cations, including a number of intercalating dyes and Qacs. However, QacB characteristically differs from QacA in that it confers significantly reduced levels of resistance to divalent cationic drugs, such as diamidines and biguanidines (8, 18). Sequence analysis and mutagenesis studies have revealed that the difference in substrate specificity between QacA and QacB is due to a single amino acid substitution at position 323 in TMS 10, where the presence of an acidic residue in QacA is essential for high levels of resistance to diamidines and biguanidines (18). The wider substrate specificity of QacA compared with QacB may have evolved in response to the clinical use of divalent cations as chemotherapeutic agents (20).

In this study, fluorescence transport assays have been utilized to measure various aspects of the bioenergetics of qacA-mediated multidrug transport. Kinetic analyses of transport of monovalent and divalent fluorescent substrates show for the first time that QacA interacts with each of its substrates with high affinity. Interactions between various substrates and QacA using competition analysis suggest that there are distinct binding sites for monovalent and divalent cations. Transport assays utilizing a membrane-specific fluorescence probe provide evidence that QacA extrudes its substrates from the inner leaflet of the cytoplasmic membrane.

    EXPERIMENTAL PROCEDURES

Bacterial Strains and Plasmids-- The S. aureus strain SK982 was used as the host strain for the qacA-encoding plasmid pSK1 and the qacB-encoding plasmid pSK23, as described previously (8). The E. coli K-12 strain BHB2600 (F'803 supE supF hsdR met) (21) was used as the host strain for the plasmid constructs pSK4219 and pSK4270, which contain the qacA and qacB genes cloned into pBluescript SK+, respectively (18). All strains were cultured at 37 °C in LB containing, where appropriate, 25 µg/ml gentamicin or 100 µg/ml ampicillin.

Chemicals-- Diamidinodiphenylamine and propamidine were provided by Rhône-Poulenc Rorer (Dagenham, United Kingdom). Benzalkonium, CCCP, chlorhexidine, DAPI, DiOC3, ethidium, nigericin, pyronin Y, reserpine, tetraphenylarsonium, TMA-DPH, valinomycin, and verapamil were all purchased from Sigma Aldrich. Nigericin and valinomycin were dissolved in 100% chloroform. Reserpine was prepared as a 1 mg/ml stock solution in 9:1 chloroform:methanol. Verapamil and TMA-DPH were solubilized in 50% and 100% methanol, respectively. CCCP was prepared as a solution in 1 mg/ml ethanol and then diluted to 0.1 mg/ml in 10 mM NaOH as described previously (22). All other chemicals were prepared as stock solutions of 1 or 10 mg/ml in water, depending on solubility, immediately prior to use.

Determination of Sensitivity to Potential Substrates and Inhibitors-- MICs of DAPI, DiOC3, reserpine, TMA-DPH, and verapamil were performed in 96-well microtiter plates. 100 µl of LB was added to each well together with increasing concentrations of the antimicrobial agent within the range of susceptibility and 1 × 10-4 dilution of an overnight culture of the strain to be tested. Plates were incubated for 48 h at 37 °C, and the MICs were determined by scoring the lowest concentration at which no growth was observed. For each compound, the MIC analysis was carried out in triplicate.

Fluorimetric Analysis of QacA- and QacB-mediated Efflux of DAPI, DiOC3, Ethidium, and Pyronin Y-- Fluorimetric assays of QacA- and QacB-mediated efflux of DAPI, DiOC3, ethidium, and pyronin Y were carried out essentially as described previously for ethidium (8). These substrates bind to specific cellular components and in so doing undergo a change in fluorescence that can be used to indicate how much of the substrate is retained by the cell, e.g. ethidium and DAPI bind to double-stranded DNA resulting in a substantial increase in fluorescence (22, 23), DiOC3, when bound to the cytoplasmic side of hyperpolarized membranes, is highly fluorescent (24), and pyronin Y binds to RNA resulting in fluorescence quenching (25). The S. aureus strain SK982, carrying the qacA-encoding plasmid pSK1 or the qacB-encoding plasmid pSK23, was grown for 16 h in 10 ml of LB (with selection) from which 1 ml was subcultured into 10 ml of fresh LB and grown to OD650 = 0.85 (~2.5 h). The E. coli strain BHB2600, carrying pSK4219 (qacA), pSK4270 (qacB) or the vector (pBluescript SK+), was grown for 16 h in 10 ml of LB (with selection) from which 1 ml was subcultured into 10 ml of fresh LB and grown to OD650 = 0.6 (~3.5 h). Cells were harvested by centrifugation, washed twice and resuspended in 10 ml of 20 mM HEPES (pH 7.0). Aliquots (1 ml) of cells were then loaded with each individual substrate (10 µM DAPI, 2.5 µM DiOC3, 15 µM ethidium, or 15 µM pyronin Y) by incubating for 1.5 h at 37 °C in the presence of 10 µM CCCP. Loaded cells were collected by centrifugation, washed three times and resuspended in 20 mM HEPES (pH 7.0). Energy-dependent efflux was assayed following the addition of sodium formate to a final concentration of 125 mM. 10 µM CCCP was used as an inhibitor in some experiments. Fluorimetric measurements were performed at 37 °C using a Hitachi 4500 fluorimeter (slit widths of 5 nm). The excitation and emission wavelengths used for each of the fluorescent compounds are as follows: DAPI, 364 nm and 454 nm, respectively; DiOC3, 485 nm and 520 nm, respectively; ethidium, 530 nm and 610 nm, respectively; and pyronin Y, 500 nm and 570 nm, respectively.

Determination of the Kinetic Parameters Km and Vmax-- Increasing substrate concentrations were used to establish the kinetics of QacA- and QacB-mediated drug efflux in E. coli and in S. aureus. Aliquots (1 ml) of cells were prepared as described above and loaded with the appropriate range of concentrations for each substrate: DAPI, 1-25 µM; DiOC3, 0.1-10 µM; ethidium, 0.1-25 µM; and pyronin Y, 1-50 µM. From these concentrations, a series of efflux curves were generated and the initial velocity was calculated by averaging the linear part of each curve. The range of substrate concentrations was selected to be equally spread above and below the Km, and a minimum of 10 substrate concentrations were utilized for each experiment. The non-linear least squares method (v = Vmax·[S]/([S] + Km)); where [S] represents substrate concentration, was the method of choice to obtain estimates of Km and Vmax. Software for the non-linear least squares method was kindly provided by Dr Ray Ritchie (School of Biological Sciences, University of Sydney) and uses a general least squares fitting technique to determine accurate estimates of Km and Vmax, followed by matrix algebra to refine and calculate the errors of these estimations (26). Km and Vmax calculations were confirmed by double-reciprocal plots where 1/velocity (v) is plotted as a function of 1/[S].

Inhibition of QacA-mediated Drug Export-- Aliquots (1 ml) of S. aureus cells were prepared as described above, loaded with 15 µM ethidium, washed three times, and resuspended in the appropriate buffer. To measure inhibition by the ionophores nigericin and valinomycin, cells were resuspended in a potassium phosphate buffer (50 mM KH2PO4 and 1.0 mM MgSO4, pH 7.0). Nigericin or valinomycin, at a final concentration of 4 µM, was added to loaded cells and incubated for 1 min followed by the addition of sodium formate, to a final concentration of 125 mM, to energize transport. To measure inhibition by reserpine and verapamil, cells were resuspended in 20 mM HEPES (pH 7.0) and 50 µM reserpine or 150 µM verapamil. Loaded cells were washed three times and resuspended in 20 mM HEPES (pH 7.0), and fluorimetric measurements were obtained after the addition of sodium formate to energize transport.

Competition Analysis-- Competition analyses were performed by determining the kinetics of QacA- and QacB-mediated export of ethidium (0.5-25 µM) in the presence of various fixed concentrations of non-fluorescent substrates, including the monovalent cations benzalkonium (2-10 µM) and tetraphenylarsonium (5-100 µM), and the divalent cations chlorhexidine (2-10 µM), propamidine (5-100 µM), and diamidinodiphenylamine (5-150 µM). Aliquots of S. aureus cells were loaded with both substrates in the presence of 10 µM CCCP for 1.5 h and harvested by centrifugation. Export of ethidium was measured fluorimetrically as described above. The results were illustrated graphically by double-reciprocal plots using the computer program Cricket Graph (Computer Associates International) to obtain a line of best fit.

Uptake of TMA-DPH into Whole Cells-- TMA-DPH specifically fluoresces in lipid environments (27) with an excitation and emission spectra of 350 nm and 425 nm, respectively (24). S. aureus strains, harboring plasmids pSK1, pSK23, or no plasmid, were prepared as described above for fluorimetric analysis. 2.5 µM TMA-DPH was added to cell suspensions, and accumulation of this substrate was measured fluorimetrically. Cells were also preloaded with 2.5 µM TMA-DPH in the presence of 10 µM CCCP as for other fluorescent substrates and efflux generated by the addition of sodium formate to a final concentration of 125 mM. 10 µM CCCP was used as an inhibitor in some experiments.

    RESULTS

QacA Mediates Export of Monovalent and Divalent Cations-- The multidrug export protein QacA confers resistance to more than 30 compounds that belong to 12 distinct chemical families (Table I; Refs. 8, 9, and 17). To establish if QacA and the closely related staphylococcal protein QacB mediate the efflux of structurally dissimilar compounds via a common mechanism, fluorimetric transport analyses of the monovalent substrates ethidium and pyronin Y, and two newly identified substrates, the monovalent cation DiOC3 (S. aureus MICs: SK982, <0.25 µg/ml; pSK1 or pSK23 in SK982, 8 µg/ml) and the divalent cation DAPI (S. aureus MICs: SK982 or pSK23 in SK982, 20 µg/ml; pSK1 in SK982, >80 µg/ml), all from different chemical families (Table I), were performed (Fig. 1). Formate-driven efflux of DAPI, DiOC3, and ethidium are shown as a rapid decrease in fluorescence, whereas efflux of pyronin Y is observed as a rapid increase in fluorescence (see "Experimental Procedures"). QacA-mediated efflux of all four substrates tested was abolished by the addition of CCCP (data not shown), an uncoupler of the PMF, which suggests that QacA mediates the extrusion of structurally dissimilar monovalent and divalent substrates via a common PMF-dependent efflux mechanism (Fig. 1). Similarly, QacB-mediated efflux of the monovalent substrates DiOC3, ethidium and pyronin Y was inhibited by CCCP. QacB demonstrated no efflux of the divalent diamidine DAPI (Fig. 1), in accord with the MIC data and previous observations that QacB confers little or no resistance to the diamidines (8, 17).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Substrates of the QacA transporter


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   Fluorimetric assays of drug transport in S. aureus. Efflux of DAPI (10 µM), DiOC3 (2.5 µM), ethidium (15 µM), and pyronin Y (15 µM) from SK982 cells harboring plasmid pSK1 (qacA, circles), plasmid pSK23 (qacB, squares), or no plasmid (background, triangles). Sodium formate (125 mM) was added at zero time to energize transport. Efflux of DAPI, DiOC3, and ethidium is represented by a rapid decrease in fluorescence, whereas efflux of pyronin Y was observed as a rapid increase in fluorescence, as described under "Experimental Procedures." Structures of each substrate are shown at the top of the appropriate graph. All efflux experiments were performed in at least triplicate.

QacA- and QacB-mediated Drug Export Conforms to Michaelis-Menten Kinetics-- There are various hypotheses that attempt to explain the broad substrate range of multidrug transporters, e.g. the transporter possesses one or more high affinity binding sites, which enables it to interact directly and specifically with its substrates, (28-30); the transporter has an indiscriminate binding mechanism, which would enable it to recognize many different structures; or the transporter is involved in altering some biophysical parameter of the cell, such as the magnitude of the Delta psi or the Delta pH, the result of which drives the movement of various charged compounds across the cell membrane (31). To determine if QacA and QacB interact specifically with structurally dissimilar substrates, kinetic analyses of transport were performed using various fluorescent substrates. These kinetic analyses, undertaken in whole cells, were based on the assumptions that after loading the cells in the presence of CCCP, the intracellular substrate concentration is effectively equivalent to the extracellular concentration, and that the use of fluorescence can accurately represent the amount of substrate inside the cell as has previously been demonstrated for ethidium, namely the amounts of ethidium retained by E. coli, calculated utilizing either fluorimetry or [14C]ethidium produced identical results (22). Consistent with these assumptions was the observation that the amount of the fluorescent substrate in loaded cells was proportional to the concentration used. Similar kinetic studies of multidrug efflux systems using whole cells have been performed in P. aeruginosa (32) and Mycobacterium smegmatis (33).

Examination of the relationship between increasing substrate concentration and the transport velocity indicated that QacA- and QacB-mediated export of monovalent and divalent cations conformed to classical Michaelis-Menten kinetics (Fig. 2), with the exception that export of DAPI by QacB was not observed at any concentration (Fig. 2B and Table II). The kinetic parameters, Km and Vmax, for transport of the fluorescent substrates DAPI, DiOC3, ethidium, and pyronin Y were determined (Table II). Similar Km values were obtained from fluorimetric analyses performed in the natural host S. aureus, and in the heterologous host E. coli, suggesting that these proteins function similarly in both organisms. Both QacA and QacB demonstrated a high affinity for their substrates with Km values in the low micromolar range (<20 µM; Table II). QacA-mediated export of monovalent cations, e.g. DiOC3, ethidium, and pyronin Y, displayed an increased Vmax, but not Km, compared with QacB-mediated efflux of these compounds (Table II), suggesting that although QacA and QacB bind monovalent substrates with equally high affinity, QacA may transport them at a faster rate.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   Michaelis-Menten kinetics of ethidium and DAPI export in S. aureus. Michaelis-Menten kinetics of export of the monovalent cation ethidium (A) and the divalent cation DAPI (B) from SK982 cells harboring plasmid pSK1 (qacA, circles) or plasmid pSK23 (qacB, squares). Efflux experiments were performed utilizing a range of drug concentrations between 0.1 and 25 µM, as described under "Experimental Procedures." Initial velocity, represented by fluorescence units per second (s-1), was plotted as a function of substrate concentration. All efflux experiments were performed in at least triplicate.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Comparative kinetic data
Estimates of Km and Vmax were calculated as described under "Experimental Procedures," and errors are shown in parentheses.

Competitive and Non-competitive Inhibition of QacA- and QacB-mediated Export of Ethidium-- Fractional inhibitory concentration analysis has indicated that QacA confers resistance to two compounds at a rate proportional to the overall amount of substrate present, thereby implying that the presence of one compound inhibits the transport of another (17). Fluorimetric competition studies were performed in S. aureus to examine QacA-mediated transport of ethidium in the presence of various non-fluorescent substrates (Fig. 3). The monovalent cations benzalkonium and tetraphenylarsonium competitively inhibited QacA-mediated export of ethidium (Fig. 3, A and B), whereas the divalent cations chlorhexidine and propamidine non-competitively inhibited QacA-mediated export of ethidium (Fig. 3, C and D). The ability of the monovalent cations benzalkonium and tetraphenylarsonium to competitively inhibit ethidium transport suggests that these substrates either share a common binding site or have unique but overlapping binding sites. In contrast, the divalent cations propamidine and chlorhexidine appear to bind at a distinct site(s) in QacA compared with ethidium.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Competitive and non-competitive inhibition of QacA-mediated ethidium transport in S. aureus. Export of the monovalent cation ethidium from SK982 cells harboring plasmid pSK1 (qacA) in the presence of non-fluorescent substrates, as described under "Experimental Procedures." Competitive inhibition is shown as a double-reciprocal plot of the kinetics of ethidium export in the presence of fixed concentrations (0 µM, squares; 5 µM, triangles; and 8 µM, circles) of the monovalent cation benzalkonium (Bc) (panel A) and a double-reciprocal plot of the kinetics of ethidium export in the presence of fixed concentrations (0 µM, squares; 20 µM, triangles; and 40 µM, circles) of the monovalent cation tetraphenylarsonium (Ta) (panel B). Non-competitive inhibition is shown as a double-reciprocal plot of the kinetics of ethidium export in the presence of fixed concentrations (0 µM, squares; 2.5 µM, triangles; and 5 µM, circles) of the divalent cation chlorhexidine (Ch) (panel C) and a double-reciprocal plot of the kinetics of ethidium export in the presence of fixed concentrations (0 µM, squares; 10 µM, triangles; and 60 µM, circles) of the divalent cation propamidine (Pi) (panel D). The computer program Cricket Graph (Computer Associates International) was utilized to obtain a line of best fit, as described under "Experimental Procedures."

QacB-mediated export of ethidium was competitively inhibited by the monovalent cations benzalkonium and tetraphenylarsonium within a similar concentration range as shown for QacA (data not shown). These data, together with the fact that QacA and QacB differ by only 7 amino acids (18) and display similar binding constants for monovalent cations (Table II), imply that these two transporters possess identical binding site(s) for monovalent substrates. The divalent cation propamidine non-competitively inhibited QacB-mediated ethidium efflux only at a substantially higher concentration (>= 40 µM) compared with QacA (10 µM; see Fig. 3D), and the divalent cation diamidinodiphenylamine did not inhibit QacB-mediated ethidium efflux even at a concentration of 150 µM. This is consistent with the resistance profile of QacB, which provides a low degree of resistance to propamidine and no resistance to diamidinodiphenylamine (8). Thus, despite the high level of similarity between QacA and QacB, they display completely different binding characteristics for divalent cations.

Inhibition of QacA-mediated Transport by Ionophores-- To investigate which component, i.e. the Delta pH and/or the Delta psi of the Delta µH+ is involved in energizing QacA-mediated drug efflux, transport assays were performed in the presence of the ionophores, valinomycin and nigericin. In potassium-buffered solutions, the potassium ionophore valinomycin specifically collapses the Delta psi , whereas nigericin, which allows H+:K+ exchange, specifically collapses the Delta pH (34). Both nigericin and valinomycin inhibited QacA-mediated efflux of ethidium (Fig. 4A) and DAPI (data not shown), indicating that both the Delta pH and the Delta psi are required to energize QacA-mediated efflux of monovalent and divalent cations. This is consistent with an electrogenic proton/antiport mechanism, e.g. an exchange of two or more protons for one molecule of substrate in the case of ethidium.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibitors of QacA-mediated ethidium export. Efflux of 15 µM ethidium from SK982 cells harboring plasmid pSK1 (qacA), in the presence of the ionophores valinomycin (4 µM, squares), nigericin (4 µM, triangles), or no addition (circles) (panel A) and verapamil (150 µM, triangles), reserpine (50 µM, squares), or no addition (circles) (panel B) as described under "Experimental Procedures." Sodium formate (125 mM) was added at zero time to energize transport. All efflux experiments were performed in at least triplicate.

Inhibition of QacA-mediated Ethidium Transport by Reserpine and Verapamil-- Sensitivity to reserpine and verapamil has been observed in an extensive range of multidrug efflux systems, including: members of the ABC superfamily, e.g. P-glycoprotein (35); the major facilitator superfamily, e.g. the mammalian VMAT protein (30), Bmr from B. subtilis (36), and LmrP from L. lactis (37); and the small multidrug resistance superfamily, e.g. EmrE from E. coli (38). MIC analysis demonstrated that QacA does not confer resistance to either reserpine or verapamil. However, both substances inhibited QacA-mediated ethidium export at a concentration of 50 µM (reserpine) or 150 µM (verapamil) (Fig. 4B).

Analysis of Accumulation and Efflux of TMA-DPH-- The hydrophobic compound TMA-DPH fluoresces when partitioned into the membrane (27), and has been utilized to identify the sub-cellular origin of efflux for various multidrug export systems (32, 37, 39). TMA-DPH was shown to be a QacA substrate by using drug susceptibility (S. aureus MICs: SK982, 15 µg/ml; pSK1 in SK982, 30 µg/ml), and formate-driven efflux (Fig. 5A) studies. TMA-DPH accumulation and efflux in cells expressing qacA were indistinguishable from cells lacking qacA, following treatment with the uncoupler CCCP (Fig. 5, A and B). It should be noted that CCCP partially quenches TMA-DPH fluorescence, resulting in the observed lower fluorescence of the CCCP-treated cells. TMA-DPH has previously been shown to display a biphasic interaction with bacterial membranes, where the first phase is represented by the intercalation of this compound into the outer leaflet of the membrane resulting in a very rapid increase in fluorescence, and the second phase is represented by the movement of this compound from the outer leaflet to the inner leaflet of the membrane resulting in a more gradual increase in fluorescence (24, 39). Fluorimetric analysis of TMA-DPH accumulation by the staphylococcal strain SK982, with and without the qacA-containing plasmid pSK1, indicated that TMA-DPH intercalates into the outer leaflet of the cytoplasmic membrane in both strains, as represented by a rapid increase in fluorescence (Fig. 5B). The first phase was observed as an almost instantaneous increase in fluorescence, occurring at approximately the 30-s point in Fig. 5B. However, the second phase, represented by a gradual increase in fluorescence, where the substrate moves from the outer leaflet to the inner leaflet of the cytoplasmic membrane, was significantly reduced in the QacA-containing strain relative to the background strain (Fig. 5B). This suggests that QacA interacts with, and expels TMA-DPH from, the cell membrane, preventing it from entering the inner leaflet and hence the cytoplasm.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   Efflux and accumulation of the fluorescent membrane probe TMA-DPH in S. aureus. A, efflux of 2.5 µM TMA-DPH from S. aureus SK982 cells harboring plasmid pSK1 (qacA, circles) or no plasmid (background, triangles). Efflux of 2.5 µM TMA-DPH from the same two strains in the presence of 10 µM CCCP was identical (squares). Sodium formate (125 mM) was added at zero time to energize transport. B, accumulation of 2.5 µM of TMA-DPH in SK982 cells harboring plasmid pSK1 (qacA, circles) or no plasmid (background, triangles). Accumulation of 2.5 µM TMA-DPH in the same two strains in the presence of 10 µM CCCP was identical (squares). The biphasic interaction of the QacA substrate TMA-DPH with the cytoplasmic membrane can be observed as follows; intercalation of TMA-DPH into the outer leaflet of the membrane is represented by the first rapid phase (at 30 s), and movement of TMA-DPH from the outer leaflet to the inner leaflet is represented by a relatively slow second phase (30 to 350 s). In both A and B, the curves obtained in the presence of CCCP (squares) were substantially lower than the corresponding curves in the absence of CCCP as CCCP quenches the fluorescence of TMA-DPH by more than 50%. Accumulation and efflux experiments were performed in at least triplicate, as described under "Experimental Procedures."


    DISCUSSION

The staphylococcal multidrug export protein QacA confers resistance to an extensive range of monovalent and divalent, antimicrobial, lipophilic compounds (Table I). QacA-mediated PMF-dependent efflux of one divalent and three monovalent cations was demonstrated by using fluorescent transport assays (Fig. 1). This suggests that QacA utilizes a common PMF-dependent efflux mechanism for transport of all of its substrates. QacA-mediated export of the monovalent cation ethidium and the divalent cation DAPI was inhibited by the ionophores nigericin and valinomycin (Fig. 4A), which specifically dissipate the Delta psi and the Delta pH, respectively. This indicates that the PMF-dependent mechanism utilized by QacA requires both components of the Delta µH+ to energize transport and implies for monovalent cations, a stoichiometry of at least two protons being exchanged for one molecule of substrate. Similar energy requirements have been shown for some other multidrug efflux systems, e.g. the mammalian VMAT proteins, which mediate monoamine antiport in exchange for two protons (40), and LmrP-mediated drug efflux from L. lactis, which is reliant on both the Delta psi and the Delta pH of the Delta µH+, suggesting an electrogenic drug/nH+ (n >=  2) antiport mechanism (37).

Fluorimetric analysis of the kinetic parameters of QacA-mediated export of DAPI, DiOC3, ethidium, and pyronin Y produced Km values in the low micromolar range, i.e. <20 µM (Table II), indicating that QacA interacts with each structurally dissimilar substrate with high affinity. Similarly, other multidrug efflux systems have been demonstrated to possess a high affinity for their substrates, e.g. Smr-mediated efflux of triphenylmethylphosphonium (Km of 5 µM) (12), and MexA/B-OprM-mediated efflux of dimethylaminostyryl-1-ethylpyridinium in P. aeruginosa (Km of 10 µM) (32). QacA and the closely related QacB share similar binding affinities for monovalent cations (Table II), and ethidium efflux mediated by these two proteins was competitively inhibited by other monovalent cations (Fig. 3, A and B). Taken collectively, these data are indicative that the QacA and QacB multidrug efflux proteins potentially utilize a common mechanism for the recognition of monovalent ligands. However, QacA and QacB differ in their recognition of divalent cations, reflected by the inability of QacB to transport DAPI (Fig. 2; Table II). QacA-mediated ethidium efflux was non-competitively inhibited by divalent cations (Fig. 3C and D), whereas QacB-mediated ethidium efflux was unaffected by diamidinodiphenylamine and non-competitively inhibited by propamidine, although only at high concentrations. These data are consistent with the relative resistance profiles conferred by QacA and QacB (8, 17). Thus, QacA appears to utilize a high affinity binding site(s) for the recognition of divalent cations, distinct from the site(s) responsible for recognition of monovalent cations; QacB lacks this high affinity binding mechanism, but is capable of binding some divalent cations, albeit with a lower affinity.

Previous studies have shown that a single amino acid, namely Asp-323 located in TMS 10 of QacA, is essential for conferring high levels of resistance to diamidines and the biguanidine, chlorhexidine, implying that this region may form part of the high affinity binding site(s) for divalent cations in QacA (18). Although QacB can interact with some divalent cations with a low affinity, mutation of Asp-323 in QacA to Ala, the residue at this position in QacB, abolished all resistance to these compounds (18). There are six additional amino acid differences between QacA and QacB, some of which are likely to be involved in forming the binding site responsible for low level resistance to the diamidines mediated by QacB. Previous studies have supported the notion that QacA evolved from QacB (20). The data presented here imply that this evolutionary process entailed the acquisition of a high affinity binding mechanism for divalent cations and the concomitant loss of a low affinity binding mechanism for selected divalent cations.

TMA-DPH is a fluorescence probe that specifically interacts with the cytoplasmic membrane. TMA-DPH was shown to be a substrate of QacA (Fig. 5A), and it was demonstrated that QacA reduces the accumulation of TMA-DPH in the inner leaflet of the cytoplasmic membrane (Fig. 5B), suggesting that QacA is most likely to interact with this substrate within the membrane. Whether the findings with TMA-DPH can be extrapolated to include all QacA substrates is unknown, but this is an appealing hypothesis, since the known substrates of QacA are all hydrophobic, lipophilic cations (Table I). The multidrug transport systems LmrP (37), MexA-MexB-OprM (32), and P-glycoprotein (41, 42) have been shown to extrude substrates directly from the cytoplasmic membrane, implying this may be a general feature of multidrug efflux systems.

The results presented here provide evidence that the multidrug transport protein QacA interacts directly and specifically with its substrates and that this interaction may occur, in the first instance, in the cell membrane as the substrate is entering the cell. Such a mechanism would prevent toxic antimicrobial agents from reaching intracellular targets. Intramembranous transporter-substrate interactions imply that critical sites in the protein are accessible directly from within the lipid phase. Residues contained within TMS, such as Asp-323 in TMS 10 of QacA, are ideal candidates for such interactions.

    ACKNOWLEDGEMENTS

We are grateful to Dr Ray Ritchie for providing statistical analysis programs for Michaelis-Menten kinetics and for valuable discussions. We thank Rhône-Poulenc Rorer for the generous supply of chemicals used in this study.

    FOOTNOTES

* This work was supported in part by a project grant from the National Health and Medical Research Council (Australia).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of an Australian Postgraduate Award.

§ Recipient of the C. J. Martin Fellowship (National Health and Medical Research Council, Australia).

To whom correspondence should be addressed: School of Biological Sciences, Macleay Bldg. A12, University of Sydney, Sydney, New South Wales 2006, Australia. Tel.: 61-2-9351-2376; Fax: 61-2-9351-4771; E-mail: skurray{at}bio.usyd.edu.au.

The abbreviations used are: PMF, proton motive force; CCCP, carbonyl cyanide m-chlorophenylhydrazone; DAPI, 4',6-diamidino-2-phenylindole; DiOC3, 3',3'-dipropyloxacarbocyanine; LB, Luria broth; MIC, minimum inhibitory concentration; Qacs, quaternary ammonium compounds; TMA-DPH, 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene; TMS, transmembrane segments; Delta psi , membrane potential; Delta pH, pH gradient; Delta µH+, transmembrane electrochemical proton gradient.
    REFERENCES
Top
Abstract
Introduction
References

  1. Gottesman, M. M., and Pastan, I. (1993) Annu. Rev. Biochem. 62, 385-427[CrossRef][Medline] [Order article via Infotrieve]
  2. Endicott, J. A., and Ling, V. (1989) Annu. Rev. Biochem. 58, 137-171[CrossRef][Medline] [Order article via Infotrieve]
  3. van Veen, H. W., Venema, K., Bolhuis, H., Oussenko, I., Kok, J., Poolman, B., Driessen, A. J. M., and Konings, W. N. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10668-10672[Abstract/Free Full Text]
  4. Griffith, J. K., Baker, M. E., Rouch, D. A., Page, M. G. P., Skurray, R. A., Paulsen, I. T., Chater, K. F., Baldwin, S. A., and Henderson, P. J. F. (1992) Curr. Opin. Cell Biol. 4, 684-695[Medline] [Order article via Infotrieve]
  5. Marger, M. D., and Saier, M. H., Jr. (1993) Trends Biochem. Sci. 18, 13-20[CrossRef][Medline] [Order article via Infotrieve]
  6. Paulsen, I. T., and Skurray, R. A. (1993) Gene (Amst.) 124, 1-11[CrossRef][Medline] [Order article via Infotrieve]
  7. Neyfakh, A. A., Bidnenko, V. E., and Chen, L. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4781-4785[Abstract]
  8. Littlejohn, T. G., Paulsen, I. T., Gillespie, M. T., Tennent, J. M., Midgley, M., Jones, I. G., Purewal, A. S., and Skurray, R. A. (1992) FEMS Microbiol. Lett. 95, 259-266[CrossRef]
  9. Tennent, J. M., Lyon, B. R., Midgley, M., Jones, I. G., Purewal, A. S., and Skurray, R. A. (1989) J. Gen. Microbiol. 135, 1-10[Medline] [Order article via Infotrieve]
  10. Paulsen, I. T., Skurray, R. A., Tam, R., Saier, M. H., Jr., Turner, R. J., Wiener, J. H., Goldberg, E. B., and Grinius, L. L. (1996) Mol. Microbiol. 19, 1167-1175[Medline] [Order article via Infotrieve]
  11. Schuldiner, S., Lebendiker, M., and Yerushalmi, H. (1997) J. Exp. Biol. 200, 335-341[Abstract/Free Full Text]
  12. Grinius, L. L., and Goldberg, E. B. (1994) J. Biol. Chem. 269, 29998-30004[Abstract/Free Full Text]
  13. Paulsen, I. T., Brown, M. H., Dunstan, S. J., and Skurray, R. A. (1995) J. Bacteriol. 177, 2827-2833[Abstract]
  14. Dinh, T., Paulsen, I. T., and Saier, M. H., Jr (1994) J. Bacteriol. 176, 3825-3831[Abstract]
  15. Poole, K., Heinrichs, D. E., and Neshat, S. (1993) Mol. Microbiol. 10, 529-544[Medline] [Order article via Infotrieve]
  16. Ma, D., Cook, D. N., Alberti, M., Pon, N. G., Nikaido, H., and Hearst, J. E. (1993) J. Bacteriol. 175, 6299-6313[Abstract]
  17. Mitchell, B. A., Brown, M. H., and Skurray, R. A. (1998) Antimicrob. Agents Chemother. 42, 475-477[Abstract/Free Full Text]
  18. Paulsen, I. T., Brown, M. H., Littlejohn, T. G., Mitchell, B. A., and Skurray, R. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3630-3635[Abstract/Free Full Text]
  19. Grkovic, S., Brown, M. H., Roberts, N. J., Paulsen, I. T., and Skurray, R. A. (1998) J. Biol. Chem. 273, 18665-18673[Abstract/Free Full Text]
  20. Paulsen, I. T., Brown, M. H., and Skurray, R. A. (1998) J. Bacteriol. 180, 3477-3479[Abstract/Free Full Text]
  21. Hohn, B. (1979) Methods Enzymol. 68, 299-309[Medline] [Order article via Infotrieve]
  22. Lambert, B., and LePecq, J. B. (1984) Biochemistry 23, 166-176[Medline] [Order article via Infotrieve]
  23. Kapuscinski, J., and Szer, W. (1979) Nucleic Acids Res. 6, 3519-3534[Abstract]
  24. Haughland, R. P. (ed) (1996) Handbook of Fluorescent Probes and Research Chemicals, Molecular Probes Inc., Eugene, OR
  25. Crissman, H. A., Darzynkiewicz, Z., Tobey, R. A., and Steinkamp, J. A. (1985) Science 228, 1321-1324[Medline] [Order article via Infotrieve]
  26. Ritchie, R. J., and Prvan, T. (1996) Biochem. Edu. 24, 196-206[CrossRef]
  27. Prendergast, F. G., Haughland, R. P., and Callahan, P. J. (1981) Biochemistry 20, 7333-7338[Medline] [Order article via Infotrieve]
  28. Pawagi, A. B., Wang, J., Silverman, M., Reithmeier, R., and Deber, C. M. (1994) J. Mol. Biol. 235, 554-564[CrossRef][Medline] [Order article via Infotrieve]
  29. Garrigos, M., Mir, L. M., and Orlowski, S. (1997) Eur. J. Biochem. 244, 664-673[Abstract]
  30. Yelin, R., and Schuldiner, S. (1995) FEBS Lett. 377, 201-207[CrossRef][Medline] [Order article via Infotrieve]
  31. Roepe, P. D. (1994) Trends Pharmacol. Sci. 15, 445-446[Medline] [Order article via Infotrieve]
  32. Ocaktan, A., Yoneyama, H., and Nakae, T. (1997) J. Biol. Chem. 272, 21964-21969[Abstract/Free Full Text]
  33. Liu, J., Takiff, H. E., and Nikaido, H. (1996) J. Bacteriol. 178, 3791-3795[Abstract]
  34. Kaback, H. R. (1986) Annu. Rev. Biophys. Biophys. Chem. 15, 279-319[CrossRef][Medline] [Order article via Infotrieve]
  35. Wigler, P. W., and Patterson, F. K. (1993) Biochim. Biophys. Acta 1154, 173-181[Medline] [Order article via Infotrieve]
  36. Ahmed, M., Borsch, C. M., Neyfakh, A. A., and Schuldiner, S. (1993) J. Biol. Chem. 268, 11086-11089[Abstract/Free Full Text]
  37. Bolhuis, H., van Veen, H. W., Brands, J. R., Putman, M., Poolman, B., Driessen, A. J. M., and Konings, W. N. (1996) J. Biol. Chem. 271, 24123-24128[Abstract/Free Full Text]
  38. Yerushalmi, H., Lebendiker, M., and Schuldiner, S. (1995) J. Biol. Chem. 270, 6856-6863[Abstract/Free Full Text]
  39. Bolhuis, H., van Veen, H. W., Molenaar, D., Poolman, B., Driessen, A., and Konings, W. N. (1996) EMBO J. 15, 4239-4245[Abstract]
  40. Njus, D., Kelley, P. M., and Harnadek, G. J. (1986) Biochim. Biophys. Acta 853, 237-265[Medline] [Order article via Infotrieve]
  41. Shapiro, A. B., and Ling, V. (1997) Eur. J. Biochem. 250, 122-129[Abstract]
  42. Shapiro, A. B., and Ling, V. (1998) Eur. J. Biochem. 254, 181-188[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.